Understanding the tumor microenvironment for effective immunotherapy.

Sadeghi Rad, H; Monkman, J; Warkiani, ME; Ladwa, R; O'Byrne, K; Rezaei, N; Kulasinghe, A

Understanding the tumor microenvironment for effective immunotherapy.

Sadeghi Rad, H Monkman, J Warkiani, ME Ladwa, R O'Byrne, K Rezaei, N Kulasinghe, A

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Medicinal Research Reviews, 2021, 41, (3), pp. 1474-1498
Issue Date:: 2021-01-01

Recently Added

	Filename	Description	Size
	Understanding the tumor microenvironment for effective immunotherapy.pdf	Published version	1.65 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is new to OPUS and is not currently available.

Full metadata record

Field	Value	Language
dc.contributor.author	Sadeghi Rad, H
dc.contributor.author	Monkman, J
dc.contributor.author	Warkiani, ME
dc.contributor.author	Ladwa, R
dc.contributor.author	O'Byrne, K
dc.contributor.author	Rezaei, N
dc.contributor.author	Kulasinghe, A
dc.date.accessioned	2022-03-08T06:29:41Z
dc.date.available	2020-11-20
dc.date.available	2022-03-08T06:29:41Z
dc.date.issued	2021-01-01
dc.identifier.citation	Medicinal Research Reviews, 2021, 41, (3), pp. 1474-1498
dc.identifier.issn	0198-6325
dc.identifier.issn	1098-1128
dc.identifier.uri	http://hdl.handle.net/10453/155076
dc.description.abstract	Advances in immunotherapy have led to durable and long-term benefits in a subset of patients across a number of solid tumor types. Understanding of the subsets of patients that respond to immune checkpoint inhibitors at the cellular level, and in the context of their tumor microenvironment (TME) is becoming increasingly important. The TME is composed of a heterogeneous milieu of tumor and immune cells. The immune landscape of the TME can inhibit or promote tumor initiation and progression; thus, a deeper understanding of tumor immunity is necessary to develop immunotherapeutic strategies. Recent developments have focused on characterizing the TME immune contexture (type, density, and function) to discover mechanisms and biomarkers that may predict treatment outcomes. This has, in part, been powered by advancements in spatial characterization technologies. In this review article, we address the role of specific immune cells within the TME at various stages of tumor progression and how the immune contexture determinants affecting tumor growth are used therapeutically.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	Medicinal Research Reviews
dc.relation.isbasedon	10.1002/med.21765
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights	This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2020 The Authors. Medicinal Research Reviews published by Wiley Periodicals LLC
dc.subject	0304 Medicinal and Biomolecular Chemistry, 0601 Biochemistry and Cell Biology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.subject.mesh	Humans
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Neoplasms
dc.subject.mesh	Tumor Microenvironment
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Tumor Microenvironment
dc.title	Understanding the tumor microenvironment for effective immunotherapy.
dc.type	Journal Article
utslib.citation.volume	41
utslib.location.activity	United States
utslib.for	0304 Medicinal and Biomolecular Chemistry
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	recently_added	*
pubs.consider-herdc	false
dc.date.updated	2022-03-08T06:29:37Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	41
utslib.citation.issue	3

Abstract:

Advances in immunotherapy have led to durable and long-term benefits in a subset of patients across a number of solid tumor types. Understanding of the subsets of patients that respond to immune checkpoint inhibitors at the cellular level, and in the context of their tumor microenvironment (TME) is becoming increasingly important. The TME is composed of a heterogeneous milieu of tumor and immune cells. The immune landscape of the TME can inhibit or promote tumor initiation and progression; thus, a deeper understanding of tumor immunity is necessary to develop immunotherapeutic strategies. Recent developments have focused on characterizing the TME immune contexture (type, density, and function) to discover mechanisms and biomarkers that may predict treatment outcomes. This has, in part, been powered by advancements in spatial characterization technologies. In this review article, we address the role of specific immune cells within the TME at various stages of tumor progression and how the immune contexture determinants affecting tumor growth are used therapeutically.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/155076